Pathology and animal models
Hovedinnhold
Background and vision
The focus of these projects are to advance the knowledge of mechanisms of disease onset and progression in MS.
Ongoing projects
Exome sequencing in multiple sclerosis
Time frame: 2016 - 2027
International cooperation
Please contact: Stig Wergeland
The oligodendrocyte proteome in multiple sclerosis
Stig Wergeland, Helse Bergen HF
Prosjektperiode:
2017 - 2023
A comprehensive comparison of myelin biomarkers in the healthy and multiple sclerosis post mortem spinal cord
Stig Wergeland, Helse Bergen HF
Prosjektperiode:
2017 - 2023
Mapping biological pathways affected by multiple sclerosis and other neurological disorders
Through our work with discovering biomarkers for multiple sclerosis we have found that many of the biological processes affected by MS also are affected by other neurological disorders. In the planned work we are aiming to analyze cerebrospinal fluid from patients with neurological disorders using the biomarker assays established by my research group at the proteomics unit, UiB (PROBE). In total we have absolute quantitative assays for more than 50 proteins in CSF, all of wich all affected by multiple sclerosis, and some of these are also affected in Parkinson’s and Alzheimer’s disease. These mass spectrometry based assays are ready to be used, making it possible to quantify all these proteins in a multiplexed fashion from a small sample volume. Using these assays as a starting point, we will screen CSF samples from several hundred patients, both with MS, PD, AD and various degrees of fatigue. The data from the complete mapping of affected CNS disease processes for every patient will be organized in an online database similar to those already established for other types of CSF proteomics data (qualitative and semi-quantiative, CSF-PR and CSF-PR 2.0). In addition, a literature screening will be conducted to extract and organize relevant absolute quantitative protein measurements in CSF of neurological disorders. The development of this database is also part of the work planned in this project. The project will shed light on important questions like which biological processes that are affected by which neurological disorder.This will have great value both when it comes to understanding the pathology for these disorders and for selecting efficient treatment strategies.
The main method in this project is based on using mass spectrometry for protein quantitation using the parallel reaction monitoring approach combined with heavy peptide spike-in of internal peptide standard for accurate protein quantitation.
Time frame: if sufficient funding is obtained, the time frame for the project outlined above is 3-4 years.
Please contact: Frode Berven
E-mail: Frode.berven@uib.no
Principal Coordinators
Lars Bø
E-mail:lars.bo@helse-bergen.no
Øivind Torkildsen
E-mail: oivind.fredvik.grytten.torkildsen@helse-bergen.no
Stig Wergeland
E-mail: stig.wergeland@helse-bergen.no
